- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02010905
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System (Redefine)
Rationale: The prevalence of adult patients with congenital heart disease (CHD) has steadily increased over the last decades, due to the advances in cardiac surgery. A large number of these patients cope with right ventricular (RV) volume or pressure overload, largely caused by residual lesions after cardiac surgery in childhood. Previous RV overload due to pulmonary regurgitation in Tetralogy of Fallot (TOF) can lead to RV dysfunction. These findings warrant close surveillance of RV function, and adequate and evidence-based pharmacological therapy to reduce both morbidity and mortality in this young patient group. The renin-angiotensin-aldosterone system (RAAS) is activated in patients with ventricular failure, irrespective of the effected (left or right) ventricle. Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB's) are drugs which act as inhibitors of RAAS. Previously, large trials have demonstrated the beneficial effect of angiotensin converting enzyme (ACE) inhibitors on morbidity and mortality in patients with acquired left ventricular (LV) dysfunction. ARB's have a similar effect as ACE inhibitors in patients with acquired LV dysfunction but discontinuation because of side effects such as cough is less frequent. In TOF patients with RV overload due to pulmonary regurgitation, pulmonary valve replacement leads to a decrease in RV size and pulmonary regurgitation. Current guidelines advise empiric use of RAAS inhibitors for right ventricular dysfunction in adult patients with congenital heart disease. However, the actual effect of RAAS inhibition on right ventricular dysfunction in adult TOF patients without severe valvular lesions has not been sufficiently investigated. Therefore, we set-up the proposed study, and hypothesize that ARB's have a beneficial effect on RV ejection fraction in adult TOF patients with RV dysfunction without severe valvular lesions.
Objective: to improve RV ejection fraction in adult TOF patients with RV dysfunction without severe valvular lesions.
Study design: a prospective, multicenter, double-blind, randomized, placebo-controlled trial. Follow up two years Study population: adult patients with Tetralogy of Fallot with right ventricular dysfunction, defined as right ventricular ejection fraction < 50% and without severe valvular lesions Intervention: patients are randomized to receive either losartan 150 mg once daily, or placebo in the same regimen. Main study parameters/endpoints: the primary endpoint is difference in change in RV ejection fraction, determined by cardiovascular magnetic resonance imaging (CMR), between the treatment and the control group at two years follow-up.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All investigations, except blood analysis, are non-invasive and free of risk. The burden for the patients mainly consists of the time that is consumed by the visits to the clinic. At these visits time will be consumed by: history taking and physical investigation (15 minutes); quality of life score (15 minutes); laboratory tests (6 times venopuncture, total amount of blood withdrawn approximately 90ml). Cardiopulmonary exercise testing (1hour), echocardiography (15 minutes) and CMR (45 minutes) are part of regular medical care. Adverse effects from losartan are usually limited and consist of dizziness due to hypotension, renal impairment, hyperkalemia and liver impairment. We expect no change or an increase in RV function in the intervention group compared to the control group over the two-year follow up period, which would be a great benefit for this young study population.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: J.P. Bokma
- Email: j.p.bokma@amc.uva.nl
Study Contact Backup
- Name: B.J. Bouma
- Email: b.j.bouma@amc.uva.nl
Study Locations
-
-
-
Amsterdam, Netherlands
- Recruiting
- Academic Medical Center
-
Principal Investigator:
- J.P. Bokma
-
Principal Investigator:
- B.J.M. Mulder
-
Principal Investigator:
- B.J. Bouma
-
Groningen, Netherlands
- Active, not recruiting
- Universitair Medisch Centrum Groningen
-
Leiden, Netherlands
- Recruiting
- Leids Universitair Medisch Centrum
-
Nieuwegein, Netherlands
- Active, not recruiting
- St Antonius Ziekenhuis
-
Nijmegen, Netherlands
- Active, not recruiting
- St Radboud Universitair Medisch Centrum
-
Utrecht, Netherlands
- Active, not recruiting
- Universitair Medisch Centrum Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to be eligible to participate in this study, a subject must meet all of the following criteria: adult age and mentally competent; and Tetralogy of Fallot; and right ventricular dysfunction, defined as right ventricular ejection fraction 50% or lower as measured by Cardiovascular Magnetic Resonance Imaging (CMR). Not more than moderate tricuspid or pulmonary regurgitation or more than moderate pulmonary stenosis as measured by CMR or echocardiography.
Exclusion Criteria:
- Incapable of giving informed consent
- Hypersensitivity to losartan or any of its help substances
- Contraindications for CMR
- Previous or current angioedema whether or not in relation to the use of an ACE inhibitor or ARB
- Known bilateral renal artery stenosis
- Current symptomatic hypotension
- Estimated glomerular filtration rate of 30 ml/min or lower
- Plasma potassium level of 5,5 mmol/L or higher
- Moderate to severe liver disease: Child Pugh class B or C
- Raised plasma transaminases level more than three times upper normal limit
- Current treatment of hypertension with an ACE-inhibitor or ARB, which cannot be discontinued
- Current treatment with potassium chloride, trimethoprim, tacrolimus or cyclosporine which cannot be discontinued
- Pregnant or nursing women
- Desire to have children within the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Losartan 150mg daily
Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm.
One time daily three tablets.
|
|
Placebo Comparator: Placebo 150mg daily
Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm.
One time daily three tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Right ventricular ejection fraction
Time Frame: two years
|
RV EF is measured by means of cardiovascular magnetic resonance imaging (CMR)
|
two years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
RV volumes (CMR)
Time Frame: two years
|
two years
|
pulmonary regurgitation (CMR and echocardiography)
Time Frame: two years
|
two years
|
aortic root diameter (CMR and echocardiography)
Time Frame: two years
|
two years
|
echocardiographic parameters for RV and LV function
Time Frame: one year and two years
|
one year and two years
|
maximal exercise capacity (VO2 max)
Time Frame: two years
|
two years
|
hospitalization for heart failure
Time Frame: two years
|
two years
|
the prevalence of (supra) ventricular arrhythmias
Time Frame: within two years
|
within two years
|
the serum ntproBNP levels
Time Frame: one year and two years
|
one year and two years
|
NYHA class
Time Frame: two years
|
two years
|
Quality of life (SF 36 and SQUASH)
Time Frame: two years
|
two years
|
death
Time Frame: two years
|
two years
|
RV mass (CMR)
Time Frame: two years
|
two years
|
LV EF (CMR)
Time Frame: two years
|
two years
|
LV volumes (CMR)
Time Frame: two years
|
two years
|
LV mass (CMR)
Time Frame: two years
|
two years
|
serum Galectin-3 levels
Time Frame: two years
|
two years
|
circulating microRNA's
Time Frame: two years
|
two years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Cardiovascular Abnormalities
- Congenital Abnormalities
- Tetralogy of Fallot
- Heart Defects, Congenital
- Ventricular Dysfunction
- Ventricular Dysfunction, Right
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Losartan
Other Study ID Numbers
- NL44943.018.13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Defects, Congenital
-
Oslo University HospitalUniversity of BergenCompletedHeart Septal Defects, Atrial | Heart Defects,CongenitalNorway
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Septal Defects, Atrial | Heart Septal Defects, Ventricular | Endocardial Cushion Defects | Defect, Congenital Heart
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Heart Septal Defects, Atrial | Heart Septal Defects, Ventricular | Endocardial Cushion Defects | Defect, Congenital Heart
-
Assiut UniversityNot yet recruitingCardiac Congenital Defects
-
SeptRx, Inc.UnknownHeart Septal Defects | Heart Defects, Congenital | Foramen Ovale, PatentGermany, France
-
Medtronic Heart ValvesCompletedDysfunctional RVOT Conduits in Patients With Congenital Heart DefectsSpain, United States, Austria, Canada
-
Zhengzhou UniversityNot yet recruitingCongenital Heart DefectChina
-
Children's Hospital of Eastern OntarioHeart and Stroke Foundation of CanadaRecruitingCongenital Heart DefectCanada
-
Medical College of WisconsinNational Center for Research Resources (NCRR); Children's Hospital and Health...Terminated
-
Ain Shams UniversityCompletedHeart Defects, CongenitalEgypt
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States